Tigecycline: A Novel Broad-Spectrum Antimicrobial

Christine M. Slover, PharmD; Keith A. Rodvold, PharmD; Larry H. Danziger, PharmD


The Annals of Pharmacotherapy. 2007;41(6):965-972. 

In This Article

Pharmacology and Mechanism of Action

Tigecycline is the first drug to be approved from the glycylcyclines, a new class of semisynthetic agents.[4] The agents in this class are being developed to overcome bacterial mechanisms of tetracycline resistance such as ribosomal protection and efflux pumps. Tigecycline has a primary backbone of minocycline with an N-alkyl-glycylamido group substituted at the 9 position, which gives this drug its broad spectrum of activity and protection from resistance mechanisms. Tigecycline is generally considered a bacteriostatic antimicrobial, but some in vitro studies have reported bactericidal activity against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria gonorrhoeae.[4,5] This drug binds to the 30S ribosomal subunit of bacteria and blocks entry of amino-acyl transfer RNA into the A site of the ribosome.[4] Tigecycline binds 5 times more efficiently to this ribosomal site compared with the tetracyclines.[6]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.